{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:30:16Z","timestamp":1790303416117,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40265-017-0737-x","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T15:45:51Z","timestamp":1491407151000},"page":"793-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Telotristat Ethyl: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"737_CR1","unstructured":"Lexicon Pharmaceuticals. XERMELO (telotristat ethyl): US prescribing information. 2017. http:\/\/xermelo.com\/Media\/Default\/pdfs\/Product_Info_telotristat_etiprate.pdf . Accessed 2 Mar 2017."},{"key":"737_CR2","unstructured":"Lexicon P. Lexicon and Ipsen enter into ex-North America\/Japan licensing and commercialization agreement for telotristat etiprate [media release]. 22 Oct 2014. http:\/\/www.lexpharma.com ."},{"key":"737_CR3","unstructured":"Lexicon P, Ipsen. Lexicon and Ipsen expand their licensing and commercialization agreement for telotristat etiprate to include Canada [media release]. 18 Mar 2015. http:\/\/www.lexpharma.com ."},{"key":"737_CR4","unstructured":"Lexicon Pharmaceuticals I. Lexicon Pharmaceuticals announces two agreements to finance long-term drug development strategy [media release]. 17 June 2007. http:\/\/www.lexpharma.com ."},{"key":"737_CR5","unstructured":"Lexicon Pharmaceuticals I. Lexicon Pharmaceuticals announces reacquisition of all rights to Symphony Icon programs [media release]. 02 Aug 2010. http:\/\/www.lexpharma.com ."},{"key":"737_CR6","unstructured":"Lexicon Pharmaceuticals. Lexicon Pharmaceuticals announces agreement to buy out remaining obligations to Symphony Icon [media release]. 05 Oct 2016. http:\/\/www.lexpharma.com ."},{"issue":"6","key":"737_CR7","doi-asserted-by":"publisher","first-page":"G455","DOI":"10.1152\/ajpgi.00299.2014","volume":"309","author":"JJ Kim","year":"2015","unstructured":"Kim JJ, Wang H, Terc JD, et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032\/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015;309(6):G455\u201365.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"737_CR8","doi-asserted-by":"publisher","unstructured":"Oravecz T, Jhaver K, Yang QM, et al. LX1606 (Aka LX1032), a peripheral inhibitor of serotonin synthesis, alleviates development of inflammatory bowel disease in a preclinical model [abstract no. Mo2021]. Gastroenterology. 2012;142(5 Supplement 1):S722.","DOI":"10.1016\/S0016-5085(12)62801-7"},{"key":"737_CR9","doi-asserted-by":"publisher","unstructured":"Pappas SC, Brown P, Turnage A, et al. LX1032: a potential new therapy for chronic diarrhea in carcinoid syndrome (CS) [abstract no. 352]. Gastroenterology. 2009;136(5 Supplement 1):A56.","DOI":"10.1016\/S0016-5085(09)60255-9"},{"issue":"1","key":"737_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol."},{"key":"737_CR11","unstructured":"Pavel M, Gross D, Benavent M, et al. Efficacy and safety results of telotristat ethyl in patients with carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial. In: North American Neuroendocrine Tumor Society Meeting. 2016."},{"key":"737_CR12","doi-asserted-by":"crossref","unstructured":"Pavel M, Benavent M, Perros P, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy results of an open-label extension of the TELECAST phase 3 clinical trial [abstract no. 1942 plus poster]. In: European Neuroendocrine Tumor Society (ENETS) Conference. 2017.","DOI":"10.1530\/ERC-17-0455"},{"issue":"5","key":"737_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/ERC-14-0173","volume":"21","author":"MH Kulke","year":"2014","unstructured":"Kulke MH, O\u2019Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705\u201314.","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"737_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1210\/jc.2014-2247","volume":"100","author":"M Pavel","year":"2015","unstructured":"Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"737_CR15","doi-asserted-by":"publisher","unstructured":"Kulke M, Horsch D, Caplin M, et al. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome [abstract no. 422PD]. Ann Oncol. 2016;27(Suppl 6):vi136\u2013vi48.","DOI":"10.1093\/annonc\/mdw369.07"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0737-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:20:21Z","timestamp":1569000021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0737-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0737-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]}}}